Armata Pharmaceuticals (ARMP) Asset Writedowns and Impairment (2017 - 2026)

Armata Pharmaceuticals (ARMP) has 9 years of Asset Writedowns and Impairment data on file, last reported at $5.6 million in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment rose 54.48% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.4 million (down 41.31% YoY), and the FY2025 full-year result was $5.4 million, down 49.8% from the prior year.
• Asset Writedowns and Impairment rose to $5.6 million in Q1 2026, from -$6.3 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $5.6 million in Q1 2026 to a low of -$6.3 million in Q4 2025.
• A 4-year average of $2.3 million and a median of $3.1 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment jumped 134.43% in 2024 and plunged 293.56% in 2025, its largest moves.
• Tracing ARMP's Asset Writedowns and Impairment over 4 years: stood at $1.4 million in 2023, then jumped by 134.43% to $3.3 million in 2024, then sank by 293.56% to -$6.3 million in 2025, then jumped by 187.63% to $5.6 million in 2026.
• Business Quant data shows ARMP's Asset Writedowns and Impairment at $5.6 million in Q1 2026, -$6.3 million in Q4 2025, and $4.3 million in Q3 2025.